Today at the American Society of Hematology 2019 conference in an MMRF session “Current Obstacles in Myeloma Management: Debating the Evidence, Dr. Saad Usmani and Dr. Rafael Fonseca faced off on the question “Should Smoldering Myeloma be Treated”?   Answer: At this time there is not enough agreement among Myeloma specialists to answer[...]

Myeloma Crowd provides the final pre #ASH19 listing of the most relevant myeloma abstracts. The listing is intended to let the participants with an interest in myeloma to find and attend the most important oral presentations. In addition, anyone following ASH by way of the internet can click on the abstracts to see what is[...]

  It’s Giving Tuesday! This year, we are donating 100% of Giving Tuesday proceeds to three cutting-edge myeloma research projects from our Myeloma Crowd Research Initiative (MCRI). Each project was carefully selected by our team and we believe each will have a lasting impact on myeloma research. Thank you to all those that have donated![...]

In recent years there has been a movement to focus on attempts to detect myeloma early, and determine when to treat to prevent debilitating organ destruction.  The infamous multiple myeloma organ damage is referred to as CRAB (High Calcium, Renal damage, Anemia, and Bone Destruction).   My first thought is CRAB is not descriptive enough[...]

  The holiday season is just around the corner, and we invite you to kick it off with us one week from today on Giving Tuesday (Dec 3)! Giving Tuesday is a global day of giving back. On the Tuesday following Thanksgiving, you’ll have the chance to join people around the world and support a[...]

Those of us who already have Darzalex as part of our multiple myeloma treatment will unquestionably be familiar with the term ‘monoclonal antibody’ (mAb). The monoclonals are antibodies that target one specific protein (CD38) that tends to be amply found on the surface of myeloma cells. The rapid growth of the inclusion of Darzalex as[...]

The American Society of Hematology 2019 (ASH) meeting will be held the first week of December. It is the largest meeting in the world on blood cancers. It is very important to know why these outstanding myeloma specialists have chosen these abstracts as the most significant.  The last blog post from Myeloma Crowd’s #ASH19 coverage[...]

  Using the antibiotic levofloxacin prior to stem cell transplant reduces death in newly diagnosed myeloma patients, according to a new study by UK myeloma research collaborators and Myeloma UK.   Infection is the leading cause of death for myeloma patients because the myeloma critically depresses the immune system. In the United Kingdom, there are[...]

Phase III results of a recent study (TOURMALINE-MM4) show that Ninlaro (ixazomib) can prolong survival when used as maintenance therapy for multiple myeloma patients who are not fit enough to receive a stem cell transplant. Ninlaro is in a class of drugs called proteasome inhibitors. Revlimid (lenalomide), an immumomodulator, is commonly used in today’s myeloma[...]

Myeloma Crowd has made it a priority to help the ASH participants interested in multiple myeloma to find the best and most relevant myeloma abstracts from the total of over 1000 myeloma abstracts listed. Each year over 30,000 Doctors, Researchers, Patient Advocates, and Patients attend the ASH conference, and to say it is confusing and overwhelming[...]